Welcome to our dedicated page for MOUNTAIN CREST ACQ V RTS news (Ticker: MCAGR), a resource for investors and traders seeking the latest updates and insights on MOUNTAIN CREST ACQ V RTS stock.
Mountain Crest Acquisition Corp. V (MCAGR) is a company focused on mergers, acquisitions, and partnerships in various industries. With a strong emphasis on growth and value creation, the company seeks to identify opportunities that will drive long-term success and shareholder value. Mountain Crest Acquisition Corp. V aims to leverage its team's expertise and network to make strategic investments that will deliver sustainable returns.
Recently, the company has been actively exploring potential targets for acquisition, evaluating market trends, and engaging in discussions with potential partners. Mountain Crest Acquisition Corp. V is committed to transparency, integrity, and responsible corporate governance, ensuring that all decisions are made in the best interest of shareholders.
Mountain Crest Acquisition Corp. V (NASDAQ: MCAG) received a deficiency notification from Nasdaq on September 13, 2024, due to delayed filing of its Q1 and Q2 2024 10-Q reports. The company has until September 16, 2024, to submit a compliance plan and may receive a maximum 180-day extension until October 14, 2024. MCAG has made progress by filing its Q1 10-Q on September 13 and submitting a compliance plan on September 16. The company also filed its previously delayed 2023 10-K on August 26, 2024. MCAG is a blank check company formed to effect a business combination with other businesses.
CUBEBIO, a Korean company with innovative early-stage cancer diagnosis technology using urine, has entered into a business combination agreement with Mountain Crest Acquisition Corp. V (MCAG). The deal aims to make CUBEBIO a publicly listed company on Nasdaq. Key details include:
1. Pre-transaction equity value for CUBEBIO: $375 million
2. Potential earn-out payment: $245 million if 2026 revenue reaches $42.7 million
3. Expected closing: First quarter of 2025
The transaction involves a merger and share swap, with CUBEBIO shareholders receiving PubCo Ordinary Shares. This marks Mountain Crest's fifth SPAC business combination, highlighting their experience in such deals.
Mountain Crest Acquisition Corp. V (NASDAQ: MCAG) has received a deficiency notification from Nasdaq due to delayed filing of its Annual Report (Form 10-K) for 2023 and Quarterly Report (Form 10-Q) for Q1 2024. This non-compliance with Nasdaq Listing Rule 5250(c)(1) requires the company to submit a compliance plan by September 2, 2024. Nasdaq may grant an extension until October 14, 2024 for the company to regain compliance. MCAG intends to file the required reports or submit a compliance plan before the deadline. The company is working to complete and file the Form 10-K and Form 10-Q as soon as possible, though no specific timing assurances were provided.
Mountain Crest Acquisition Corp. V and CUBEBIO Co., have entered a non-binding term sheet for a potential business combination. CUBEBIO, a Korea-based company, with innovative cancer diagnosis technology using urine, aims to become a public company listed on The Nasdaq Stock Market. The pre-transaction equity value is $620 million, subject to adjustments. Global Fund is advising CUBEBIO. Mountain Crest V's management expresses excitement about the growth potential from CUBEBIO's technology.
FAQ
What is the current stock price of MOUNTAIN CREST ACQ V RTS (MCAGR)?
What is the core focus of Mountain Crest Acquisition Corp. V?
What is the company's approach to growth and value creation?
How does Mountain Crest Acquisition Corp. V select potential targets for acquisition?
What values guide the decisions of Mountain Crest Acquisition Corp. V?
Who leads Mountain Crest Acquisition Corp. V?
Where is Mountain Crest Acquisition Corp. V located?
How can I contact Mountain Crest Acquisition Corp. V?
What recent developments has Mountain Crest Acquisition Corp. V experienced?
What is Mountain Crest Acquisition Corp. V's goal for its investments?
How does Mountain Crest Acquisition Corp. V ensure shareholder interests are protected?
